Literature DB >> 9703956

Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells.

J L Mehta1, D Y Li.   

Abstract

Although macrophages scavenge oxidatively modified low density lipoprotein (ox-LDL) via specific receptors, the uptake of ox-LDL by endothelial cells is thought to be mediated by a different receptor (LOX-1). We examined the presence of LOX-1 on cultured human coronary artery endothelial cells (HCAECs) by RT-PCR, radioligand blot, and binding assays. LOX-1 mRNA and protein were consistently identified in HCAECs. [125I]-ox-LDL binding assay also identified high affinity binding sites for LOX-1 on HCAECs (KD: 1.71 x 10(-8) M: Bmax: 29.7 ng/mg protein). There was no change in LOX-1 expression in HCAECs treated with native-LDL. In contrast, incubation of HCAECs with ox-LDL (10-40 micrograms/ml) increased LOX-1 expression (mRNA and protein). The upregulation of LOX-1 expression appeared to be dependent on ox-LDL concentration. Higher concentration (100 micrograms/ml) however, decreased LOX-1 expression, perhaps related to its cytotoxic effect. These observations indicate that ox-LDL upregulates its own receptor on HCAECs. This phenomenon may explain enhanced uptake of ox-LDL by HCAECs in hyperlipidemia resulting in cellular dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703956     DOI: 10.1006/bbrc.1998.9004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding.

Authors:  M Chen; S Narumiya; T Masaki; T Sawamura
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

2.  Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis.

Authors:  Tanu Goyal; Sona Mitra; Magomed Khaidakov; Xianwei Wang; Sandeep Singla; Zufeng Ding; Shijie Liu; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2012-01-29       Impact factor: 5.113

3.  The lectin-like oxidized low-density lipoprotein receptor and its role in atherosclerosis.

Authors:  Mehmet Cilingiroglu; Kerem Ozer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 4.  LOX-1, a new marker of risk and prognosis in coronary artery disease?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2013-08-11       Impact factor: 3.396

5.  Regulation of Coronary Endothelial Function by Interactions between TNF-α, LOX-1 and Adiponectin in Apolipoprotein E Knockout Mice.

Authors:  Xiuping Chen; Hanrui Zhang; Michael A Hill; Cuihua Zhang; Yoonjung Park
Journal:  J Vasc Res       Date:  2016-04-07       Impact factor: 1.934

6.  OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators.

Authors:  Anthony J Valente; Anand M Irimpen; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Free Radic Biol Med       Date:  2014-02-20       Impact factor: 7.376

Review 7.  Regulation of foam cells by adenosine.

Authors:  Allison B Reiss; Bruce N Cronstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

8.  A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1.

Authors:  M Kakutani; T Masaki; T Sawamura
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

9.  Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis.

Authors:  Jiawei Chen; Yong Liu; Hongmei Liu; Paul L Hermonat; Jawahar L Mehta
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

10.  The type 1 diabetes - HLA susceptibility interactome--identification of HLA genotype-specific disease genes for type 1 diabetes.

Authors:  Caroline Brorsson; Niclas Tue Hansen; Regine Bergholdt; Søren Brunak; Flemming Pociot
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.